化合物IRL 2500 T15596

Product Introduction
Bioactivity


英文名: IRL 2500

描述: IRL 2500 是内皮素受体的拮抗剂，对内皮素 A 受体和内皮素 B 受体的 IC50 分别为 1.3 和 94 nM。

体内活性: In the anesthetized rat, IRL 2500 (10 mg/kg; i.v.) decreases the IRL 1620-mediated enhances renal vascular resistance. IRL 2500 suppresses the initial transient reduction in mean arterial pressure induced by IRL 1620[1]. IRL 2500 (10 mg/kg; i.v.) pre-treatment reduces the initial vasodepressor response to endothelin-1 and IRL 1620 without altering the secondary and sustained pressor response[2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 93.6 mg/mL (163.2 mM)


关键字: IRL 2500 | IRL-2500 | IRL2500

相关产品: Macitentan | SB-209670 | Sitaxsentan sodium | BQ-123 | Bosentan | Darusentan | Ambrisentan | Aminaftone | Atrasentan | Ro 46-2005

相关库: Neurotransmitter Receptor Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | GPCR Compound Library | Bioactive Compound Library

化合物IRL 2500 T15596信息由TargetMol中国为您提供，如您想了解更多关于化合物IRL 2500 T15596报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途